Shelley Hartman Left Goldman Sachs to Bet on the Cell’s Tiny Messengers

After nineteen years in investment banking, Shelley Hartman traded advice for execution. At Aegle Therapeutics, she is turning an elegant piece of university science into a clinical-stage company, one painstaking milestone at a time.